• For Patients
• Important Safety Information
• AstraZeneca Web Sites

• Home
• About ZOMIG
• Professional Resources
• Patient Resources
  • Patient Downloads
• Virtual Rep
• Prescribing Information

• 

Who are today's migraneurs? Nearly 1 in 4 U.S. households include someone who suffers from migraines. Over 27 million of them are women.¹⁴

Here are resources you can share with today’s migraineurs to help them track their migraines, learn more about migraines, and talk to you about migraine management.

Migraine Tracker

This migraine tracker will encourage your patients to learn more about their migraines by tracking and discussing the pattern of their migraines.

This easy-to-use migraine diary will help your patients record their migraine triggers, pain intensity, pain duration, and effectiveness of treatment each time they experience a migraine. This information may prove helpful as you and your patients work out a migraine management plan that works best for them.

Download Migraine Tracker as PDF

Migraine Disability Assessment Scale (MIDAS) Questionnaire

The MIDAS questionnaire will help your patients tell you about the impact of their migraines.

The MIDAS questionnaire is designed to help your patients learn about how migraines impact their lives. Tracking the effect migraines have on their lives may prove helpful as you and your patients work to develop an appropriate migraine management plan.

Select the MIDAS questionnaire format that best fits your practice:

Migraine Trigger Chart

This migraine trigger chart will help your patients learn about common migraine triggers.

Even though the actual cause of migraines has not been determined, certain foods and physical/emotional situations may help set off, or trigger, migraines. Using this chart will help your patients know their individual triggers. Identifying their migraine triggers may prove helpful as you and your patients work to develop an appropriate migraine management plan.

Download Migraine Trigger Chart as PDF

Patient Web Site for ZOMIG

Encourage your patients to visit our patient-focused www.ZOMIG.com.

Here patients can find special programs and materials about migraine pain, its treatment, and what they can do to help ensure the success of their migraine management program.

Other Patient Web Resources

News, migraine information, and migraine support 24/7.

Provide your patients with a listing of online resources that they can access day or night for educational information, migraine support groups, and message boards, available at our patient-focused www.zomig.com/what/resources.aspx.

Indication and Important Safety Information

Indication

ZOMIG is indicated for the acute treatment of migraine with or without aura in adults.

ZOMIG should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with ZOMIG, the diagnosis of migraine should be reconsidered before ZOMIG is administered to treat any subsequent attacks. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population.

Important Safety Information

• ZOMIG is contraindicated in patients with
  • Ischemic heart disease (eg, silent ischemia, angina), coronary artery vasospasm, or other significant underlying cardiovascular disease
  • Cerebrovascular syndromes (eg, history of stroke or TIA)
  • Peripheral vascular disease (eg, ischemic bowel disease)
  • Uncontrolled hypertension
• Use of ZOMIG is contraindicated within 24 hours of another 5-HT₁ agonist, ergotamine-containing or ergot-type medication, or within 2 weeks of an MAO-A inhibitor
• ZOMIG should not be administered to patients with hemiplegic or basilar migraine
• It is strongly recommended that ZOMIG not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors without a satisfactory cardiac evaluation
• Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory cardiac conduction pathways should not receive ZOMIG
• Development of a potentially life-threatening serotonin syndrome may occur with triptans particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
• Phenylketonuric patients should be informed that ZOMIG-ZMT^® (zolmitriptan) Orally Disintegrating Tablets contains phenylalanine
• ZOMIG should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus
• Side Effects: The most common adverse reactions in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
• Side Effects: The most common adverse reactions in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness

Please click here for full Prescribing Information for ZOMIG Tablets and ZOMIG-ZMT Orally Disintegrating Tablets

Please click here for full Prescribing Information for ZOMIG Nasal Spray